ODS, NCI research grants
This article was originally published in The Tan Sheet
Applications for R01, R21 grants to conduct "innovative preclinical and clinical research to determine how diet and dietary factors impact DNA methylation and other epigenetic processes involved with cancer prevention" requested by ODS, National Cancer Institute in recent RFA. Collaboration between nutrition and epigenetic/ DNA methylation experts "to study bioactive food components with cancer preventative properties" is encouraged. NCI will fund seven to 10 grants in FY 2004 with a total of $2.5 mil; ODS will offer $800,000 for three or four grants that year. Letters of intent are due by Feb. 18, applications one month later. Under a separate but related RFA, researchers "can extend the goals of active grants to include studies related to the impact of diet and nutrition on epigenetic events"...
You may also be interested in...
Shortly after wrapping up a Phase III trial for its proposed generic Advair Diskus product in the US, Cipla has won FDA approval for the first generic Proventil HFA product, as it continues to build up steam in the US respiratory market.
The UK's MHRA is looking for manufacturers to submit COVID-19 self-tests that meet minimum and desired criteria for evaluation, after finding its recently purchased 3.5m self-tests failed to meet these standards. Criteria include no requirement for testing knowledge or training or assistance from a healthcare professional in administering or interpreting the results of the test, as well as a 95% accuracy level.
Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.